Using a blood marker to improve heart attack treatment decisions
Validation of Platelet Expression of FcɣRIIa as a Precision Tool
This study is looking at a blood marker called FcγRIIa to help doctors create more personalized treatment plans for people at risk of heart problems, aiming to improve their care while reducing the chances of bleeding complications.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Prolocor INC. NIH-funded |
| Lab location | 1 site (Shelburne, United States) |
| Project ID | NIH-11238227 on NIH RePORTER |
What this research studies
This research investigates the use of a specific blood marker, FcγRIIa, found on platelets, to better tailor anti-thrombotic therapy for patients at risk of coronary events. By identifying patients' thrombotic risk more accurately, the study aims to optimize treatment duration and intensity, potentially reducing unnecessary bleeding complications. The approach involves analyzing platelet function and the expression of FcγRIIa to guide personalized treatment plans for individuals with acute coronary syndrome. This could lead to more effective management of heart attack risks based on individual patient profiles.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with a history of acute coronary syndrome who are at varying levels of thrombotic risk.
Not a fit: Patients who do not have a history of cardiovascular events or those with low-risk profiles may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more personalized and effective treatment strategies for patients at risk of heart attacks, minimizing complications and improving outcomes.
How similar studies have performed: Previous research has shown promise in using biomarkers for precision medicine in cardiovascular care, but this specific approach with FcγRIIa is relatively novel.
Where this research is happening
Shelburne, United States
- Prolocor INC. — Shelburne, United States (Active)
Researchers
- Principal investigator: Ohrnberger, Jeanne — Prolocor INC.
- Study coordinator: Ohrnberger, Jeanne
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.